Early low dose Oral ImmunoTherapy (OIT) in children with an established food allergy

The aim of this research project is to assess the safety, feasibility and clinical effectiveness of early low-dose oral immunotherapy in children under the age of 30 months with an established food allergy on the induction of long-term tolerance. Primary outcome for clinical effectiveness is sustained unresponsiveness (long-term tolerance) assessed by an exit oral food challenge at 4 weeks after discontinuation of the oral immunotherapy, combined with an unclomplicated consumption of a full dose of food (4,2 gram food protein) at least weekly at 6 months after discontinuing the therapy.

This research project on oral immunotherapy in young children with a food allergy has been started in 2019 with a safety and feasibility study. Inclusion of new participants in the feasibility study will end spring 2022. A multi-center study on the effectiveness of oral immunotherapy will be started in the second half of 2022.

Contact 
Lieke Barten